Back to top
more

BioMarin Pharmaceutical (BMRN)

(Delayed Data from NSDQ)

$66.60 USD

66.60
1,644,379

+0.71 (1.08%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $66.63 +0.03 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

BioMarin (BMRN) Q4 Earnings Top Estimates, Sales Fall Y/Y

by Zacks Equity Research

Biomarin Pharmaceutical's (BMRN) fourth-quarter earnings and sales beat estimates. Stock declines

BioMarin Pharmaceutical (BMRN) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

BioMarin (BMRN) delivered earnings and revenue surprises of 250% and 1.22%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Drug/Biotech Stocks' Q4 Earnings on Feb 23: BMRN, BHC & More

by Zacks Equity Research

Let us take a look at five drug/biotech companies, namely, BMRN, CLVS, TBPH, BHC and GBT, which are due to release their quarterly results on Feb 23.

Ekta Bagri headshot

4 Biotechs That Could Be Potential Takeover Targets in 2022

by Ekta Bagri

We discuss a few companies like BioMarin (BMRN), Adaptimmune (ADAP), CRISPR Therapeutics (CRSP), and Alnylam Pharmaceuticals (ALNY) with solid product portfolios, deep pipelines which make them attractive candidates for a potential takeover in 2022.

Biotech Stock Roundup: Drug Approvals for BMRN, Updates From BIIB, BMY, MRNA & More

by Zacks Equity Research

Drug approvals for BioMarin (BMRN) and regulatory updates from Biogen (BIIB), among others, have been the biotech sector's few key highlights during the past week.

BioMarin Pharmaceutical (BMRN) Just Flashed Golden Cross Signal: Do You Buy?

by Zacks Equity Research

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

BioMarin's (BMRN) Dwarfism Drug Gets FDA's Nod, Stock Up

by Zacks Equity Research

Biomarin Pharmaceuticals's (BMRN) Voxzogo is the first medicine in the United States to be approved to treat achondroplasia, the most common form of dwarfism.

Wall Street Analysts Believe BioMarin (BMRN) Could Rally 37%: Here's is How to Trade

by Zacks Equity Research

The mean of analysts' price targets for BioMarin (BMRN) points to a 37.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

BioMarin (BMRN) Beats on Q3 Earnings, Ups 2021 Guidance

by Zacks Equity Research

BioMarin's (BMRN) earnings beat estimates in the third quarter of 2021 while revenues miss the same. The company raises total revenue guidance and increases adjusted earnings guidance for 2021.

BioMarin Pharmaceutical (BMRN) Q3 Earnings Surpass Estimates

by Zacks Equity Research

BioMarin (BMRN) delivered earnings and revenue surprises of 63.64% and -5.35%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate BioMarin Pharmaceutical (BMRN) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biotech Stock Roundup: MRNA Submits Vaccine Data, BMRN Down on Clinical Hold & More

by Zacks Equity Research

Regulatory and pipeline updates from Moderna (MRNA) and BioMarin (BMRN), among others, have been in focus in the biotech industry over the past week.

BioMarin (BMRN) Phenylketonuria Gene Therapy on Clinical Hold

by Zacks Equity Research

BioMarin's (BMRN) phase I/II study on gene therapy candidate, BMN 307, has been placed under a clinical hold by the FDA possibly on malignancy concerns.

BioMarin's (BMRN) Dwarfism Drug Gets Approval in Europe

by Zacks Equity Research

Biomarin Pharmaceutical's (BMRN) Voxzogo is the first medicine in Europe to be approved to treat achondroplasia, the most common form of dwarfism.

Stock Market News for Aug 30, 2021

by Zacks Equity Research

Benchmarks closed higher on Friday with the S&P 500 and Nasdaq hitting fresh all-time highs after Federal Reserve Chair Jerome Powell assured that they might taper bond purchases this year, but interest rate hikes are still far away.

Why Is BioMarin (BMRN) Up 0.4% Since Last Earnings Report?

by Zacks Equity Research

BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

BioMarin (BMRN) Beats on Q2 Earnings, Ups 2021 Guidance

by Zacks Equity Research

BioMarin (BMRN) beats on both earnings and revenues in the second quarter of 2021.

Merck (MRK) Q2 Earnings Miss, Sales Rebound, Stock Slips

by Zacks Equity Research

Merck (MRK) misses Q2 estimates for earnings but beats the same for sales. Stock down in pre-market.

BioMarin Pharmaceutical (BMRN) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

BioMarin (BMRN) delivered earnings and revenue surprises of 76.67% and 11.78%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

BioMarin (BMRN) Upgraded to Strong Buy: Here's What You Should Know

by Zacks Equity Research

BioMarin (BMRN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Repligen (RGEN) Beats on Q2 Earnings & Sales, Ups 2021 View

by Zacks Equity Research

Repligen (RGEN) reports encouraging second-quarter results, with sales and earnings beating estimates. The company also raises its guidance for 2021. Resultantly, the stock rises.

Drug/Biotech Stock Earnings on Jul 28: PFE, GSK, BMY, BMRN & TLRY

by Zacks Equity Research

Let us take a look at five drug/biotech companies - PFE, GSK, BMY, BMRN and TLRY - which are gearing up for their earnings release.

Arvinas (ARVN), Pfizer Team up for Breast Cancer Therapy

by Zacks Equity Research

Arvinas (ARVN) collaborates with Pfizer for its investigational breast cancer candidate, ARV-471. Pfizer is also set to acquire an equity stake in Arvinas. The stock rises 9% post the announcement.

Novartis' (NVS) Q2 Earnings Top Estimates as Businesses Recovers

by Zacks Equity Research

Novartis (NVS) reports mixed results for the second quarter, as key brands maintain momentum and businesses show signs of recovery.

Analysts Estimate BioMarin Pharmaceutical (BMRN) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.